- Home
- RMAX vs ELDN Comparison
RMAX vs ELDN Comparison
Compare RMAX & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMAX | ELDN |
|---|---|---|
| Founded | 1973 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.9M | 291.8M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RMAX | ELDN |
|---|---|---|
| Price | $12.36 | $3.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $11.40 | $8.50 |
| AVG Volume (30 Days) | 696.8K | ★ 872.7K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $195,929,000.00 | N/A |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $1.24 | N/A |
| P/E Ratio | $20.60 | ★ N/A |
| Revenue Growth | ★ 11.13 | N/A |
| 52 Week Low | $5.46 | $1.35 |
| 52 Week High | $14.63 | $4.60 |
Technical Indicators
Market Signals| Indicator | RMAX | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 35.97 |
| Support Level | $8.95 | $2.68 |
| Resistance Level | N/A | $4.21 |
| Average True Range (ATR) | 0.89 | 0.16 |
| MACD | 0.17 | -0.03 |
| Stochastic Oscillator | 56.09 | 4.13 |
Price Performance
Historical ComparisonAbout RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.